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Abstract
Background: Increased incidence of cardiovascular diseases (CVD) in both HIV infection and type 2 diabetes (T2D)
compared to the general population has been described. Little is known about the combined effect of HIV
infection and T2D on inflammation and endothelial function, both of which may contribute to elevated risk of CVD.
Methods: Cross-sectional study including 50 HIV-infected persons on combination anti-retroviral therapy (cART),
with HIV RNA <200 copies/mL (n = 25 with T2D (HIV + T2D+), n = 25 without T2D (HIV + T2D-)) and 50 uninfected
persons (n = 22 with T2D (HIV-T2D+) and n = 28 without T2D (HIV-T2D-)). Groups were matched on age and sex.
High sensitive C-reactive protein (hsCRP) was used to determine inflammation (cut-off 3 mg/L). The marker of
endothelial dysfunction asymmetric dimethylarginine (ADMA) was measured using high performance liquid
chromatography. Trimethylamine-N-oxide (TMAO), a microbiota-dependent, pro-atherogenic marker was measured
using stable isotope dilution LC/MS/MS.
Results: The percentage of HIV + T2D+, HIV + T2D-, HIV-T2D+, and HIV-T2D- with hsCRP above cut-off was 50%,
19%, 47%, and 11%, respectively. HIV + T2D+ had elevated ADMA (0.67 μM (0.63-0.72) compared to HIV + T2D- (0.
60 μM (0.57-0.64) p = 0.017), HIV-T2D+ (0.57 μM (0.51-63) p = 0.008), and HIV-T2D- (0.55 μM (0.52-0.58) p < 0.001).
No differences in TMAO between groups were found. However, a positive correlation between ADMA and TMAO
was found in the total population (rs = 0.32, p = 0.001), which was mainly driven by a close correlation in
HIV + T2D+ (rs = 0.63, p = 0.001).
Conclusion: Elevated inflammation and evidence of endothelial dysfunction was found in HIV-infected persons
with T2D. The effect on inflammation was mainly driven by T2D, while both HIV infection and T2D may contribute
to endothelial dysfunction. Whether gut microbiota is a contributing factor to this remains to be determined.
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Background
Introduction of combination anti-retroviral therapy
(cART) has increased life expectancy for HIV-infected
persons. However, new challenges are emerging, and in-
cidence of cardiovascular disease (CVD) is increased in
HIV-infected persons compared to the general
population [1]. Chronic inflammation resulting in endo-
thelial dysfunction and atherosclerosis may contribute to
increased risk of CVD in HIV infection [2].
Type 2 diabetes (T2D) is also characterized by chronic
inflammation and endothelial dysfunction [3], and T2D is
an independent risk factor for CVD in the general popula-
tion as well as in the HIV-infected population [3, 4]. In
HIV infection, it is debated if prevalence of T2D is higher
than in the general population [5–7]. Traditional T2D risk
factors including age and obesity as well as HIV-related
factors such as some cART regimes and chronic
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inflammation are found to be associated with develop-
ment of T2D in HIV-infected populations [8–10]. Thus,
with an aging HIV-infected population and an emerging
worldwide diabetes epidemic, a combination of HIV infec-
tion and T2D may become a clinical challenge.
Asymmetric dimethylarginine (ADMA) is elevated in
both HIV infection and T2D [11, 12]. ADMA is an en-
dogenous inhibitor of endothelial NO synthase and a well-
established marker of endothelial dysfunction [13]. L-
Arginine is the natural precursor for NO in the endothe-
lium. L-arginine/ADMA ratio is important since ADMA,
by a competitive reversible blocking of NO-production
from L-arginine, affects endothelial function [13, 14].
The gut microbiota is altered in both HIV infection
and in T2D [15, 16], and studies suggest that altered
microbiota is associated with increased inflammation
[17, 18]. Recently, trimethylamine-N-oxide (TMAO) a
metabolite from dietary carnitine and choline was found
to promote atherosclerosis and predict CVD in persons
with T2D as well as HIV-uninfected cohorts [19, 20].
Production of TMAO seems to be dependent on metab-
olism by gut microbiota, as one week of antibiotics is
sufficient to block its formation [19, 21, 22]. Since the
gut microbiota is altered in both HIV infection and in
T2D [15, 16] elevated TMAO may contribute to inflam-
mation and endothelial dysfunction in these patients.
Little is known about the combined effect of HIV infec-
tion and T2D on inflammation and endothelial function.
The aim of this study was to determine if concurrent T2D
in HIV-infected persons results in higher levels of inflam-
mation and endothelial dysfunction compared to either
HIV infection by itself or T2D in uninfected persons. We
hypothesized that higher inflammation and elevated
markers of endothelial dysfunction would be found in per-
sons with both HIV and T2D compared to persons with
either HIV or T2D. TMAO was included in our study to
explore a possible link between gut microbiota, inflammation
and endothelial function in patients with HIV infection and
T2D. We determined inflammation, endothelial dysfunction,
and the potential contribution of gut microbiota by measur-
ing high sensitive C-reactive protein (hsCRP), ADMA, L-
arginine, and TMAO in HIV-infected persons with T2D
(HIV + T2D+) and three control groups: HIV-infected
persons without T2D (HIV + T2D-), uninfected persons with
T2D (HIV-T2D+), and healthy controls (HIV-T2D-).
Methods
Participants
We performed a cross-sectional study including 100 par-
ticipants (25 HIV + T2D+, 25 HIV + T2D-, 22 HIV-T2D
+, and 28 HIV-T2D-). ADMA was the main outcome in
this study. In a previous study ADMA was determined
in HIV-positive individuals, mean (standard deviation)
was 0.59 μM (0.31, 23]. In that study, individuals with
T2D were not included. However, in other studies in un-
infected individuals with metabolic syndrome or T2D
and 48% and 130% increase in ADMA was found com-
pared to controls [12, 24]. Assuming the same difference
between HIV-infected individuals with and without T2D
(0.59 μM vs. 0.87 μM), power = 0.8, and alpha = 0.05, a
minimum of 20 individuals are needed in each group.
We included at least 22 individuals in each group. Inclu-
sion criteria for HIV-infected persons were treatment
with cART and suppressed viral replication (HIV
RNA < 200 copies/mL.) Inclusion criteria for persons
with T2D were confirmed T2D with one or more of the
following: HbA1c > 48 mmol/mol (2 tests), fasting blood
glucose >7 mmol/l (2 tests), or 2 h blood glucose level
on >11.1 mmol/L after a glucose tolerance test. Also, all
persons with T2D were treated with diet and/or oral
anti-diabetics and/or insulin. All persons without T2D
should have normal fasting glucose (<6.1 mmol/L) and
HbA1c < 48 mmol/mol. Exclusion criteria were im-
munosuppressive treatment, acute infections, malig-
nancy, and pregnancy. All HIV-infected persons with
T2D attending regular controls at the Department of In-
fectious Diseases at University Hospital of Copenhagen,
Rigshospitalet or Hvidovre Hospital, and who fulfilled
inclusion and exclusion criteria, were invited to partici-
pate in the study. Participants in the three control
groups were recruited in order to match for age and sex.
Inclusion was stopped when at least n = 22 in each
group and a total of n = 100 was reached.
Patients with T2D were included from the Department
of Endocrinology, and Center of Inflammation and Me-
tabolism, University Hospital of Copenhagen, Rigshospi-
talet. Healthy controls were recruited among hospital
staff. All HIV-positive participants included in the study
had a confirmatory positive HIV test. A negative HIV
test was not performed for participants in the uninfected
control groups, since the prevalence of HIV in Denmark
is 0.1%, and it seems reasonable to assume that clinical
healthy participants are HIV-negative. Six HIV-T2D+
also participated in another study concerning the effect
of short duration, high-intensity interval training on
endothelial function and metabolism (on going). Partici-
pants were included before training.
The Framingham Risk Score was calculated based on
gender, age, height, weight, current smoking status, dia-
betes, ECG-left ventricular hypertrophy, systolic blood
pressure, total cholesterol, and HDL. The calculation
was performed using Risk Assessment Tool System
available by Centre of Excellence for Health, Immunity
and Infectious Diseases (CHIP) [25].
The study was performed in accordance with the Dec-
laration of Helsinki and approved by the local ethical
committee (H-4-2012-076 CIM VEK) and the Danish
Data Protection Agency.
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Laboratory analyses
Fasting blood samples were collected from all participants.
HIV RNA was measured in HIV-infected persons and glu-
cose, HbA1c, CD4+ and CD8+ count were measured in
all participants as routine analyses at the time of inclusion.
HsCRP was determined using immunoturbidimetric ana-
lysis (Tina-quant hsCRP latex assay, Roche/Hitachi,
Cobas, Mannheim, Germany). Data on hsCRP were only
available on 87 participants. A cut-off at 3 mg/L was used
to assess high risk of CVD [26].
ADMA and L-arginine were measured in snap-frozen
EDTA plasma by high performance liquid chromatography
and precolumn derivatization with o-phthaldialdehyde
(Sigma Chemicals Co, St. Louis, MO, USA) as described
[27]. Inter-assay CV’s were <5% for both assays.
Stable isotope dilution liquid chromatography with
tandem mass spectrometric (LC/MS/MS) was used for
quantification of TMAO. TMAO was monitored in posi-
tive multiple reaction monitoring (MRM) MS mode
using characteristic precursor-product ion transitions:
m/z 76 → 58 as described [22]. All stable isotope labeled
internal standards were from Cambridge Isotope Labora-
tories, Inc., Andover, MA, USA.
Statistical analyses
Data were tested for normal distribution, and logarith-
mic transformation was used as appropriate. Results are
given as mean and 95% Confidence Interval (95% CI) or
geometric mean (95% CI). Differences between groups
were analyzed using one-way ANOVA and t test. Corre-
lations were done using Pearson correlation. Pearson
chi-square test was used on categorical data. Further-
more, potential predictors of endothelial dysfunction
were investigated in a linear regression analysis. HsCRP
and TMAO were not normally distributed and therefore
log-transformed before analyses. Two-tailed p-values
<0.05 were considered significant. Statistical analyses
were performed using SPSS version 20 (SPSS, Inc.; Chi-
cago, IL, USA) and GraphPad Prism 5 (GraphPad Soft-
ware, San Diego, CA, USA).
Results
Study population
Characteristics of study participants are displayed in
Table 1. There was no difference in age or sex between
the groups. The HIV + T2D+ and HIV + T2D- groups
had comparable CD4+, CD8+ and nadir CD4+ cell
counts, HIV RNA, treatment duration, and time since
HIV diagnosis. However, Body Mass Index (BMI) was
higher in HIV-T2D+ compared to other groups. The
Framingham Risk Score was used calculating the 10-year
risk of CVD in the four groups [25]. As expected a sig-
nificant difference between groups was found (Table 1).
However, since diabetes is included in The Framingham
Risk Score calculation, the groups with identical diabetes
status were compared. The calculated 10 years risk of
CVD did not differ between HIV + T2D+ and HIV-T2D
+ or between HIV + T2D- and HIV-T2D- (Table 1).
Table 1 Characteristics of the study population. Data presented as mean and 95% CI.Differences between groups are analyzed
using one-way ANOVA or Pearson chi-square test. Results are given as mean and 95% Confidence Interval. a, b, c, d are analyzed
using t-test; a: p > 0.05 vs. HIV + T2D-, b: p < 0.05 vs. HIV + T2D-, c: p > 0.05 vs. HIV-T2D+, d: p < 0.05 vs. HIV-T2D+. BMI: Body Mass
Index
N HIV + T2D+ HIV + T2D- HIV-T2D+ HIV-T2D- P
25 25 22 28
Age (years) 58 (55–61) 55 (50–58) 57 (53–60) 57 (55–60) 0.638
Gender (% male) 92 96 89 72 0.079
CD4 count (cells/μL) 672 (554–790)a 663 (520–807) 1254 (980–1528) 849 (720–978) <0.001
CD8 count (cells/μL) 994 (675–1312)a 884 (645–1124) 567 (428–706) 458 (372–544) 0.001
Nadir CD4 (cells/μL) 180 (121–240) 266 (171–360) − − 0.392
HIV RNA (copies/mL) 26 (16–38) 27 (15–40) − − 0.757
Time since HIV diagnosis (months) 200 (153–248) 172 (112–232) − − 0.740
Treatment duration (months) 143 (116–170) 124 (89–159) − − 0.394
Fasting BG (mmol/L) 8.0 (6.9-9.0)b,c 5.3 (5.0-5.4) 9.0 (7.9-10.3) 5.3 (5.1-5.6) <0.001
HbA1c (mmol/mol) 48 (44–52)b,d 35 (33–37) 60 (54–65) 36 (32–39) <0.001
BMI 26 (24–28)a,d 25 (23–27) 28 (27–30) 25 (24–26) 0.007
Smoking (%) 44 24 23 21 0.233
Systolic BP (mmHg) 132 (125–139) 127 (121–133) 138 (131–144) 135 (130–140) 0.115
Diastolic BP (mmHg) 82 (77–87) 80 (77–84) 86 (82–91) 82 (79–85) 0.317
CVD10 (Framingham Risk Score) 29 (22–35)c 14 (10–18) 25 (19–30) 16 (12–20)a <0.001
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Infection with hepatitis C virus (HCV) was not an ex-
clusion criterion in this study. However, only two partic-
ipants were infected with HCV one in the HIV + T2D+
and one in HIV + T2D- group.
Increased inflammation in HIV + T2D+ compared to
HIV + T2D-
HIV + T2D+ had a higher hsCRP compared to
HIV + T2D- and HIV-T2D- (3.2 (0.86-12.0) vs. 1.5 (0.6-
3.8) p = 0.032 and 1.1 (0.48-2.8) p = 0.002, respectively)
but not compared to HIV-T2D+ (3.2 (0.86-12.0)) vs. 2.8
(0.48-2.8), p = 0.860). The percentage of HIV + T2D+,
HIV + T2D-, HIV-T2D+ and HIV-T2D- with hsCRP
above cut-off (3 mg/L) was 50%, 19%, 47% and 11%, re-
spectively (Fig. 1a). More participants with HIV + T2D+
had hsCRP above cut-off compared to HIV + T2D- and
HIV-T2D- but not compared to HIV-T2D+ (p = 0.05,
p = 0.003 and p = 0.935, respectively).
To further investigate potential predictors of inflam-
mation, a multivariate linear regression analysis was per-
formed adjusting for age, gender, group (HIV + T2D+,
HIV + T2D-, HIV-T2D+, and HIV-T2D-), BMI, CD4
count, and current smoking. The analysis was performed
on the total study population (n = 100). Both group vari-
able and current smoking were associated with hsCRP in
multivariate analyses (p = 0.031 and p = 0.010, respect-
ively) (Table 2). Adjusting for TMAO did not alter this
association. Correlations between hsCRP and TMAO
were not found in the total population or in any of the
groups (data not shown).
Higher ADMA in HIV + T2D+ compared to HIV + T2D-
HIV + T2D+ had higher concentration of ADMA com-
pared to HIV + T2D-, HIV-T2D+, and HIV-T2D-
(0.67 μM (0.63-0.72) vs. 0.60 μM (0.57-0.64), p = 0.017
and 0.57 μM (0.51-0.63), p = 0.008 and 0.55 μM (0.52-
0.58), p < 0.001, respectively) (Fig. 1b).
L-arginine/ADMA ratio was lower in HIV + T2D+
compared to HIV + T2D- and HIV-T2D- (102 (93–111)
vs. 123 (111–135), p = 0.007) and 138 (125–151),
p < 0.001, respectively), but not compared to HIV-T2D+
(102 (93–111) vs. (115 (102–128), p = 0.109 (Fig. 1c).
To further investigate potential predictors of endothe-
lial dysfunction, a multivariate linear regression analysis
was performed adjusting for age, gender, group
(HIV + T2D+, HIV + T2D-, HIV-T2D+, and HIV-T2D-
Fig. 1 High sensitive C-reactive protein (hsCRP), Asymmetric dimethylarginine (ADMA), L-arginine/ADMA ratio and Trimethylamine N-oxide (TMAO)
levels in the four groups: HIV-infected persons with type 2 diabetes (HIV + T2D+), HIV-infected persons without type 2 diabetes (HIV + T2D-), unin-
fected persons with type 2 diabetes (HIV-T2D+) and healthy controls(HIV-T2D-). Differences between groups were analyzed using one-way anova
followed by t test. a hsCRP. Blue line shows a cut-off at 3 mg/L indicating high risk of CVD. For statistical analysis logarithmic transformation was used
on data on hsCRP. The figure shows data before logarithmic transformation. b: ADMA, c L-arginine/ADMA ratio and d TMAO
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), BMI, CD4 count, and current smoking. The analysis
was performed on the total study population (n = 100).
The group variable predicted endothelial dysfunction
(p < 0.001) (Table 2). In addition, we found a significant
interaction between TMAO and group on elevated
ADMA level, with TMAO being closely associated with
ADMA in HIV + T2D+ (Additional file 1: Table S3).
When adding TMAO to the multivariate model, TMAO
was also independently associated with ADMA (Table
2). Of note, the beta coefficient of group status in pre-
dicting ADMA levels remained unchanged.
Correlation between ADMA and TMAO in HIV infection
No differences in concentration of TMAO between
groups were found (Fig. 1d). However, in the total popu-
lation, there was a moderate positive correlation be-
tween TMAO and ADMA (rs = 0.32, p = 0.001), which
was driven by a strong correlation in HIV + T2D+
(rs = 0.63, p = 0.001), and not significant in the other
groups (HIV + T2D-: rs = 0.35, p = 0.088, HIV-T2D+;
rs = −0.20, p = 0.374, HIV-T2D-; rs = 0.20, p = 0.305).
Discussion
Both HIV infection and T2D are characterized by
chronic inflammation and increased risk of CVD. Lit-
tle is known about the combined effect of HIV and
T2D. In this study, higher ADMA and lower L-
arginine/ADMA ratio was found in HIV + T2D+
compared to all three control groups indicating endo-
thelial dysfunction. Furthermore, we found that 50%
of HIV + T2D+ had hsCRP above 3 mg/L indicating
an increased risk of CVD [26]. In contrast, only 19%
of HIV + T2D- had hsCRP above cut-off. Interest-
ingly, HIV + T2D+ displayed comparable level of in-
flammation compared to HIV-T2D+. Concentration of
TMAO was comparable in the four groups, but a
positive correlation between ADMA and TMAO was
found mainly to be driven by persons with
HIV + T2D+ suggesting an association between gut
microbiota and endothelial dysfunction in this group.
Higher ADMA and lower L-arginine/ADMA ratio
were found in patients with both HIV infection and
T2D, indicating increased endothelial dysfunction in pa-
tients with both HIV infection and T2D. Importantly,
only disease group was associated with ADMA in a
multivariate linear regression model minimizing the risk
of possible confounders. This finding may be of clinical
relevance since studies in HIV-infected populations have
found elevated ADMA to be independently associated
with pulmonary arterial hypertension and increased cor-
onary artery calcium score [28, 29]. Furthermore, in the
setting of T2D, elevated ADMA was found to be associ-
ated with macrovascular disease [30]. Finally, ADMA
was previously shown to enhance the predictive value of
hsCRP for CVD in patients with T2D [31].
A recent study found elevated ratio between ADMA
and systemic dimethylarginine (SDMA) in HIV infec-
tion. SDMA is produced from the same substrate as
ADMA but not metabolized by the same enzyme [11,
32]. This finding indicates that the mechanism of
ADMA accumulation in HIV infection is related to re-
duced activity of the enzyme dimethylarginine dimethy-
laminohydrolase which is responsible for metabolism of
ADMA. This may be a consequence of oxidative stress
generated from chronic inflammation. This is in agree-
ment with our findings of elevated ADMA and hsCRP
in patients with HIV + T2D+.
Chronic inflammation is associated with increased risk
of CVD in the general population and in HIV infection
[33–35]. In a multivariate linear regression model both
smoking and disease group were associated with hsCRP.
It is well known that smoking is associated with inflam-
mation in both HIV-infected and uninfected persons
[36, 37]. In the “Simple Trial Comparing Two Strategies
for Management of Anti-Retroviral Therapy” (SMART
study), elevated inflammation was found in HIV-infected
persons when compared to the general population [38].
In our study, difference in hsCRP between HIV + T2D-
and HIV-T2D- was not found, possibly due to low sam-
ple size or to a well-treated population receiving ART.
Table 2 BMI:Body Mass Index, TMAO: Trimethylamine-N-oxide
Multiple Linear Regression Models with ADMA and hsCRP as Dependent Variables
Characteristics Unstandardized Coefficient β (95% CI) Model with
ADMA
t P Unstandardized Coefficient β (95% CI) Model
with hsCRP
t P
Group 0.033 (0.016 to 0.049) 3.990 <0.001 0.104 (0.010 to 0.198) 2.202 0.031
Age 0.001 (−0.002 to 0.004) 0.771 0.443 0.010 (−0.007 to 0.026) 1.164 0.248
Gender −0.048 (−0.104 to 0.007) −1.732 0.087 −0.009 (−0.366 to 0.348) −0.051 0.960
BMI 0.002 (−0.003 to 0.006) 0.746 0.457 0.007 (−0.022 to 0.036) 0.471 0.639
Smoking −0.005 (−0.046 to 0.036) −0.234 0.816 0.323 (0.081 to 0.566) 2.651 0.010
CD4+ cell
count
-4.256E-5 (0.000 to 0.000) −1.607 0.112 8.914 E-5 (0.000 to 0.000) 0.576 0.567
LogTMAO 0.088 (0.029 to 0.147) 2.953 0.004 −0.120 (−0.462 to 0.222) −0.698 0.487
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In contrast, inflammation seemed closely linked to T2D.
Thus, a very high percentage of participants with T2D
(both with and without HIV infection) had hsCRP above
cut-off indicating both that chronic inflammation is an
essential part in the pathogenesis of T2D in persons with
and without HIV-infection and a high risk of CVD in
both groups. An independent association between
chronic inflammation and increased risk of developing
T2D is well established [39]. Furthermore, obesity is a
well-known risk factor for developing T2D, and studies
have shown that obesity and chronic inflammation are
tightly linked [40]. This fits well with our finding of ele-
vated BMI in HIV-T2D+. In contrast, no difference in
BMI was found in HIV + T2D+ compared to HIV + T2D-
and HIV-T2D-, indicating different pathogenesis leading
to T2D in HIV-infected and uninfected persons. We
speculate that HIV infection and the resulting chronic
inflammation alter the balance between insulin sensitiv-
ity and insulin production. However, this is speculative
and cannot be validated in a cross-sectional study.
Formation of TMAO depends on both dietary intake
containing choline or carnitine and on the composition of
the gut microbiota [19]. Elevated TMAO has been re-
ported to be associated with cardiovascular events in per-
sons with T2D as well as in the general population [19, 20,
22]. In a recent study of HIV-infected individuals, TMAO
was increased in patients with myocardial perfusion de-
fects. However no association to first-time myocardial in-
farction was found [41]. In our population, concentration
of TMAO was comparable in all groups. This is consistent
with recent studies reporting no difference in TMAO be-
tween HIV infected persons and healthy controls or per-
sons with T2D and healthy controls [41, 42]. However, a
larger study reported higher TMAO in persons with dia-
betes compared to healthy controls [20], and consensus
has not been reached. In the present study, a positive cor-
relation between TMAO and ADMA was observed.
TMAO interferes with reverse cholesterol transportation
and promotes foam cell formation and atherosclerosis
[43]. Since endothelial dysfunction is an early step in the
atherosclerotic process, this association is not surprising
and it fits well with our previous finding of a close associ-
ation between soluble CD14 and ADMA in HIV-infected
persons on cART [23]. However, it is intriguing that the
correlation was driven by the group of HIV + T2D+, and
the association was not significant in either HIV + T2D-
or HIV-T2D+. It may indicate an interacting effect of the
two diseases possibly mediated by alterations in the gut
microbiota. Further research to determine the possible
clinical impact of this is warranted.
Inflammation is a possible link between TMAO and
CVD. However, no correlations were found between
hsCRP and TMAO. To our knowledge no other studies
have investigated hsCRP and TMAO in HIV infection or
T2D. Our finding is consistent with recent studies in
healthy individuals [44, 45]. Albeit, an association between
TMAO and TNF-α has been found [45]. Hence, the rela-
tion between TMAO and inflammation remains unclear.
The present study is limited by sample size and the
cross sectional design, and it is not possible to conclude
on causal relationship. Furthermore, the study is limited
by the lack of HIV testing in the uninfected control
groups. All participants in the uninfected control groups
were without any symptoms, and the prevalence of HIV
infection in Denmark is low (0.1%). Thus, it seems rea-
sonable to assume these participants were uninfected.
However, it would have been more accurate if an HIV
test had been performed on all participants when in-
cluded in the study. Unfortunately, plasma was only
available for hsCRP measurements in 87 participants.
The proportion of participants with hsCRP measure-
ments was comparable in the four groups. However, the
missing data represents a limitation to the study. The
prevalence of smoking in the group of HIV + T2D+
seemed to be higher than in the other groups, although
this was not significant. Since smoking was associated
with inflammation this may be a limitation regarding
our data on hsCRP. Also, ADMA is a relatively novel
biomarker and little data on clinical endpoints exists.
However, a large study in uninfected participants from
The Framingham Offspring Cohort found that ADMA
and L-arginine/ADMA ratio was associated with all-
cause mortality after a follow-up period of 10.9 years
[46]. A recent systemic review, including 22 prospective
studies, found ADMA associated with CVD [47]. Never-
theless, comparisons between the well-defined and
highly prevalent disease categories included in this study
are, to our knowledge, novel. Larger prospective studies
to determine if ADMA is associated with clinical end-
points in HIV-infected persons, especially in HIV-
infected persons with T2D, would be very interesting.
Conclusions
In conclusion, our findings imply that elevated inflam-
mation and endothelial dysfunction could be factors
contributing to elevated risk of CVD in HIV-infected
persons with T2D, compared to HIV- infected persons
without T2D. The possible combined effect of HIV in-
fection and T2D, and the potential role of gut micro-
biota in this regard, should be further investigated. With
an aging HIV-infected population, lifestyle diseases and
co-morbidity are emerging clinical challenges. This high-
lights the importance of CVD preventive strategies and
close clinical monitoring for cardiovascular risk factors
in HIV-infected persons with T2D. Finally, research tar-
geting possible anti-inflammatory treatments to reduce
chronic inflammation in HIV-infected persons is
warranted.
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Additional file
Additional file 1: Table S3. HIV+T2D+: HIV infected persons with type
2 diabetes, TMAO: Trimethylamine-N-oxide. (PPTX 46 kb)
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